Critical Pharmacodynamic Warning

acetaminophen affects the 1A2 metabolic pathway.

When patients take acetaminophen concurrently with drugs metabolized by 1A2, the risk of adverse effects may significantly increase. This interaction affects drug clearance and systemic exposure, potentially leading to toxicity or reduced therapeutic efficacy.

Clinical Impact: As a moderate inhibitor , acetaminophen can alter the metabolism of substrate drugs, requiring careful monitoring and potential dose adjustments.

Clinical Overview for acetaminophen

This page outlines known interaction pathways involving acetaminophen, focusing primarily on its profile as a Moderate inhibitor affecting the 1A2 pathway.

Enzyme Interaction Profile

acetaminophen demonstrates moderate inhibitor potency against 1A2. Clinical significance of this interaction requires further evaluation.

Inhibitor

A substance that slows down or prevents an enzyme from metabolizing a drug. Inhibitors can lead to increased drug concentrations in the body, potentially causing toxicity or enhanced therapeutic effects.

Clinical Example: acetaminophen affects 1A2

Inducer

A substance that speeds up enzyme activity, causing drugs to be cleared from the body faster. Inducers can reduce drug effectiveness by lowering concentrations below therapeutic levels.

Known Inducers: rucaparib
Interaction Details
Drug Name acetaminophen
Affected Enzyme 1A2
Inhibitor Strength Moderate inhibitor Unknown
Inducers rucaparib
Inhibitors vemurafenib
Clinical Recommendations

Consult primary literature for guidance.

Monitoring Parameters:
  • Therapeutic drug levels
  • Adverse effect monitoring
  • Clinical response assessment
Dose Considerations:
  • Consider dose reduction
  • Evaluate alternative therapies
  • Adjust based on response
Quick Facts
Interaction ID
13162
Primary Pathway
1A2
Interaction Type
Enzyme Inhibition
Clinical Phase
Unknown
Clinical Significance

Clinical significance requires further evaluation.

Information Sources
  • FDA Drug Interaction Database
  • Clinical Pharmacology Guidelines
  • Pharmaceutical Labeling Information
  • Published Clinical Studies
Last updated: June 13, 2026
Back Return to Database